Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Bioxyne Limited ( (AU:BXN) ) has shared an announcement.
Bioxyne Limited has announced the issuance of 1,200,000 ordinary fully paid securities as part of an agreement to issue shares in lieu of cash payment for an invoice. This move is part of the company’s strategic financial management, potentially impacting its liquidity and shareholder value by conserving cash while fulfilling financial obligations.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
More about Bioxyne Limited
Bioxyne Limited operates in the biotechnology industry, focusing on the development and commercialization of health and wellness products. The company is known for its probiotic and health supplement products, targeting both domestic and international markets.
Average Trading Volume: 2,764,348
Technical Sentiment Signal: Buy
Current Market Cap: A$85.4M
See more data about BXN stock on TipRanks’ Stock Analysis page.